Stephanie Vitz1,2, Holger Göbel3,2, Bernhard Leibl4,2, Thomas Aigner5,2, Gerhard G Grabenbauer6,7. 1. Department of Radiation Oncology, Coburg Hospital, Ketschendorfer Str. 33, 96450, Coburg, Germany. 2. Coburg Cancer Centre, Coburg Hospital, Coburg, Germany. 3. Department of Gastroenterology, Helmut G. Walter Hospital Lichtenfels, Lichtenfels, Germany. 4. Visceral and Abdominal Surgery, Coburg Hospital, Coburg, Germany. 5. Department of Pathology, Coburg Hospital, Coburg, Germany. 6. Department of Radiation Oncology, Coburg Hospital, Ketschendorfer Str. 33, 96450, Coburg, Germany. gg@diestrahlentherapeuten.de. 7. Coburg Cancer Centre, Coburg Hospital, Coburg, Germany. gg@diestrahlentherapeuten.de.
Abstract
PURPOSE: To retrospectively evaluate long-term treatment results following neoadjuvant chemoradiation (CRT) and radical surgery in patients with advanced adenocarcinoma (AC) of the oesophagus. PATIENTS AND METHODS: Between 2005 and 2015, a total of 102 consecutive patients with a median age of 64 years (range, 44-86 years) and AC of the oesophagus were evaluated of whom 84 received a full CRT. A group of 51 patients was treated with neoadjuvant intent followed by radical surgery. A total dose of 50.4 Gy with mostly weekly paclitaxel/fluorouracil chemotherapy was administered. Six to eight weeks following CRT, a transthoracic subtotal oesophageal and proximal gastric resection was performed. Survival curves for overall survival and no evidence of disease (NED) survival (primary endpoints) were calculated according to Kaplan-Meier, and possible prognostic factors were evaluated by the log-rank test as well as by a Cox regression analysis. RESULTS: Median follow-up time of the surviving patients was 48 months (range, 14-134 months). Overall and NED survival rates for patients of the study group (n = 51) were 40 and 32%, respectively, at 5 years. Age (p = 0.04), ypT category (p = 0.1) and the development of distant metastases (p = 0.05) were identified as (marginally) independent prognostic variables with impact on survival. Median survival time for patients of the study group (n = 51) was 45 ± 18 months (95%CI 9-81 months). Clear resection margins were achieved in 46/51 patients (92%). Regression rates with complete regression rare residual cancer and increased number of residual cells, but predominantly fibrosis were 33, 41, and 10%, respectively. Patterns of failure revealed local with distant recurrence in 2/51 (4%), regional recurrence alone in 2/51 (4%), and distant metastases in 27/51 (53%) patients. CONCLUSION: Neoadjuvant CRT in patients with AC of the oesophagus followed by thoracoabdominal surgery is a locally very effective concept. A significant tumour regression in almost 75% of the patients may stimulate prospective trials on the omission of radical surgery for some elderly patients. Due to a high rate of distant metastases further investigations in terms of effective systemic therapy may be warranted.
PURPOSE: To retrospectively evaluate long-term treatment results following neoadjuvant chemoradiation (CRT) and radical surgery in patients with advanced adenocarcinoma (AC) of the oesophagus. PATIENTS AND METHODS: Between 2005 and 2015, a total of 102 consecutive patients with a median age of 64 years (range, 44-86 years) and AC of the oesophagus were evaluated of whom 84 received a full CRT. A group of 51 patients was treated with neoadjuvant intent followed by radical surgery. A total dose of 50.4 Gy with mostly weekly paclitaxel/fluorouracil chemotherapy was administered. Six to eight weeks following CRT, a transthoracic subtotal oesophageal and proximal gastric resection was performed. Survival curves for overall survival and no evidence of disease (NED) survival (primary endpoints) were calculated according to Kaplan-Meier, and possible prognostic factors were evaluated by the log-rank test as well as by a Cox regression analysis. RESULTS: Median follow-up time of the surviving patients was 48 months (range, 14-134 months). Overall and NED survival rates for patients of the study group (n = 51) were 40 and 32%, respectively, at 5 years. Age (p = 0.04), ypT category (p = 0.1) and the development of distant metastases (p = 0.05) were identified as (marginally) independent prognostic variables with impact on survival. Median survival time for patients of the study group (n = 51) was 45 ± 18 months (95%CI 9-81 months). Clear resection margins were achieved in 46/51 patients (92%). Regression rates with complete regression rare residual cancer and increased number of residual cells, but predominantly fibrosis were 33, 41, and 10%, respectively. Patterns of failure revealed local with distant recurrence in 2/51 (4%), regional recurrence alone in 2/51 (4%), and distant metastases in 27/51 (53%) patients. CONCLUSION: Neoadjuvant CRT in patients with AC of the oesophagus followed by thoracoabdominal surgery is a locally very effective concept. A significant tumour regression in almost 75% of the patients may stimulate prospective trials on the omission of radical surgery for some elderly patients. Due to a high rate of distant metastases further investigations in terms of effective systemic therapy may be warranted.
Authors: Lucas Goense; Pieter C van der Sluis; Peter S N van Rossum; Sylvia van der Horst; Gert J Meijer; Nadia Haj Mohammad; Marco van Vulpen; Stella Mook; Jelle P Ruurda; Richard van Hillegersberg Journal: J Surg Oncol Date: 2017-03-07 Impact factor: 3.454
Authors: Bernhard J Leibl; Stephanie Vitz; Wolfgang Schäfer; Martin Alfrink; Andreas Gschwendtner; Gerhard G Grabenbauer Journal: Strahlenther Onkol Date: 2011-03-24 Impact factor: 3.621
Authors: K Kumagai; I Rouvelas; J A Tsai; D Mariosa; P A Lind; M Lindblad; W Ye; L Lundell; C Schuhmacher; M Mauer; B H Burmeister; J M Thomas; M Stahl; M Nilsson Journal: Eur J Surg Oncol Date: 2014-11-27 Impact factor: 4.424
Authors: S M Lagarde; M Navidi; S S Gisbertz; H W M van Laarhoven; K Sumpter; S L Meijer; B Disep; A Immanuel; S M Griffin; M I van Berge Henegouwen Journal: Br J Surg Date: 2016-10-03 Impact factor: 6.939
Authors: F Klevebro; G Alexandersson von Döbeln; N Wang; G Johnsen; A-B Jacobsen; S Friesland; I Hatlevoll; N I Glenjen; P Lind; J A Tsai; L Lundell; M Nilsson Journal: Ann Oncol Date: 2016-01-17 Impact factor: 32.976
Authors: Holger H Göbel; Luitpold V R Distel; Thomas Aigner; Maike J Büttner-Herold; Gerhard G Grabenbauer Journal: Clin Transl Radiat Oncol Date: 2022-04-03
Authors: R Fietkau; R Grützmann; U A Wittel; R S Croner; L Jacobasch; U P Neumann; A Reinacher-Schick; D Imhoff; S Boeck; L Keilholz; H Oettle; W M Hohenberger; H Golcher; W O Bechstein; W Uhl; A Pirkl; W Adler; S Semrau; S Rutzner; M Ghadimi; D Lubgan Journal: Strahlenther Onkol Date: 2020-09-10 Impact factor: 3.621